These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33406335)

  • 41. An African plan to control COVID-19 is urgently needed.
    The Lancet
    Lancet; 2020 Dec; 396(10265):1777. PubMed ID: 33278920
    [No Abstract]   [Full Text] [Related]  

  • 42. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Audio Interview: Protecting the Immunosuppressed against Covid-19.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 May; 384(21):e88. PubMed ID: 34042395
    [No Abstract]   [Full Text] [Related]  

  • 44. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
    Tabll AA; Shahein YE; Omran MM; Elnakib MM; Ragheb AA; Amer KE
    Hum Antibodies; 2021; 29(3):179-191. PubMed ID: 33998533
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Maximizing number of doses drawn from multi-dose COVID-19 vaccines by minimizing dead-volume.
    Le Daré B; Bacle A; Lhermitte R; Lesourd F; Lurton Y
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33772277
    [No Abstract]   [Full Text] [Related]  

  • 46. Audio Interview: Covid-19 and the States - A Conversation with Ralph Northam.
    Rubin EJ; Baden LR; Northam RS; Morrissey S
    N Engl J Med; 2021 Feb; 384(5):e25. PubMed ID: 33534981
    [No Abstract]   [Full Text] [Related]  

  • 47. A million-dose success for Nepal: insights from Nepal's national vaccine deployment plan against COVID-19.
    Bhattarai S; Dhungana J
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33668060
    [No Abstract]   [Full Text] [Related]  

  • 48. Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy.
    Narożna M; Rubiś B
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Restoring confidence in vaccines in the COVID-19 era.
    Verger P; Dubé E
    Expert Rev Vaccines; 2020 Nov; 19(11):991-993. PubMed ID: 32940574
    [No Abstract]   [Full Text] [Related]  

  • 50. Mix-and-match COVID vaccines: the case is growing, but questions remain.
    Lewis D
    Nature; 2021 Jul; 595(7867):344-345. PubMed ID: 34211168
    [No Abstract]   [Full Text] [Related]  

  • 51. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.
    Shahverdi M; Darvish M
    Curr Mol Med; 2021; 21(7):562-572. PubMed ID: 33272178
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross-Reactive SARS-CoV-2 Neutralizing Antibodies From Deep Mining of Early Patient Responses.
    Bullen G; Galson JD; Hall G; Villar P; Moreels L; Ledsgaard L; Mattiuzzo G; Bentley EM; Masters EW; Tang D; Millett S; Tongue D; Brown R; Diamantopoulos I; Parthiban K; Tebbutt C; Leah R; Chaitanya K; Ergueta-Carballo S; Pazeraitis D; Surade SB; Ashiru O; Crippa L; Cowan R; Bowler MW; Campbell JI; Lee WJ; Carr MD; Matthews D; Pfeffer P; Hufton SE; Sawmynaden K; Osbourn J; McCafferty J; Karatt-Vellatt A
    Front Immunol; 2021; 12():678570. PubMed ID: 34211469
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New challenges to fighting COVID-19: Virus variants, potential vaccines, and development of antivirals.
    Chen J; Lu H
    Biosci Trends; 2021 May; 15(2):126-128. PubMed ID: 33746183
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
    Casadevall A; Henderson JP; Joyner MJ; Pirofski LA
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33621214
    [No Abstract]   [Full Text] [Related]  

  • 55. COVID-19 vaccines approved in the European Union: current evidence and perspectives.
    Bellino S
    Expert Rev Vaccines; 2021 Oct; 20(10):1195-1199. PubMed ID: 34338126
    [No Abstract]   [Full Text] [Related]  

  • 56. COVID-19 Pandemic and Virtual Clinics for Diabetes Care.
    Garg SK; Reinicke T
    Diabetes Technol Ther; 2021 Jun; 23(S2):S3-S15. PubMed ID: 34061640
    [No Abstract]   [Full Text] [Related]  

  • 57. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19.
    Ward BJ; Gobeil P; Séguin A; Atkins J; Boulay I; Charbonneau PY; Couture M; D'Aoust MA; Dhaliwall J; Finkle C; Hager K; Mahmood A; Makarkov A; Cheng MP; Pillet S; Schimke P; St-Martin S; Trépanier S; Landry N
    Nat Med; 2021 Jun; 27(6):1071-1078. PubMed ID: 34007070
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rectifying COVID-19 disparities with treatment and vaccination.
    Carethers JM
    JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33476304
    [No Abstract]   [Full Text] [Related]  

  • 59. Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Dec; 385(25):e100. PubMed ID: 34910868
    [No Abstract]   [Full Text] [Related]  

  • 60. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors.
    Frieman M; Harris AD; Herati RS; Krammer F; Mantovani A; Rescigno M; Sajadi MM; Simon V
    EBioMedicine; 2021 Jun; 68():103401. PubMed ID: 34051441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.